Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00382070 · ClinicalTrials.gov registry record · Phase 3
Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer
A Phase 3 study of Breast Cancer, sponsored by NSABP Foundation.
- Active
- Registry status
- Phase 3
- Development phase
- 3,966
- Enrollment target
- 20
- Study locations
NCT00382070: Active Phase 3 study of Breast Cancer, sponsored by NSABP Foundation.
NCT00382070 is a Phase 3 study of Breast Cancer that is active but no longer recruiting, run by NSABP Foundation. The registered enrollment target is 3,966 participants, above the 2,800-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (42% higher). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00382070, a Phase 3 study of Breast Cancer, is active but no longer recruiting, sponsored by NSABP Foundation.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 3,966 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by lowering the amount of estrogen the body makes. It is not yet known whether letrozole is more effective than a placebo in treating patients with hormone receptor-positive breast cancer. PURPOSE: This randomized phase III trial is studying letrozole to see how well it works compared with a placebo in treating postmenopausal women who have received hormone therapy for hormone receptor-positive breast cancer.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Letrozole
Study Locations (20)
California
- Alta Bates Summit Comprehensive Cancer Center - Berkeley
- Providence Saint Joseph Medical Center - Burbank - Burbank
- Peninsula Medical Center - Burlingame
- East Bay Radiation Oncology Center - Castro Valley
- Eden Medical Center - Castro Valley
- Valley Medical Oncology Consultants - Castro Valley - Castro Valley
- Cancer Care Center at John Muir Health - Concord Campus - Concord
- City of Hope Comprehensive Cancer Center - Duarte
- North Bay Cancer Center - Fairfield
- Kaiser Permanente - Fremont - Fremont
- Valley Medical Oncology - Fremont
- Cancer Care Associates - Fresno
- Virginia K. Crosson Cancer Center at St. Jude Medical Center - Fullerton
- Glendale Memorial Hospital Comprehensive Cancer Center - Glendale
- Marin Cancer Institute at Marin General Hospital - Greenbrae
Alabama
- Regional Medical Center - Anniston
- Providence Cancer Center at Providence Hospital - Mobile
Alaska
- Providence Cancer Center - Anchorage
- Fairbanks Cancer Treatment Center at Fairbanks Memorial Hospital - Fairbanks
Arkansas
- Arkansas Cancer Research Center at University of Arkansas for Medical Sciences - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,966 participants |
| Start Date | 2006-08 |
| Est. Completion | 2025-04 |
| Phase | Phase 3 |
What the registry record for NCT00382070 still lists
NCT00382070 is an interventional study that assigns participants to a tested intervention. Its 3,966 participants enrollment target places it among the larger protocols in the corpus, above the 2,800-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (42% higher).
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00382070 names 20 study sites across 4 states, led by California, Alabama, Alaska.
Frequently Asked Questions
What is clinical trial NCT00382070 about?
NCT00382070 is a clinical study titled "Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer". RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by lowering the amount of estrogen the body makes. It is not yet known whether letrozole is more effective than a placebo in treating patients with hormone receptor-positive breas...
What is the current status of trial NCT00382070?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 3,966 participants. The study started on 2006-08. Estimated completion is 2025-04.
What conditions does trial NCT00382070 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT00382070?
The interventions under investigation include: Placebo (OTHER), Letrozole (DRUG).
Who is sponsoring clinical trial NCT00382070?
This trial is sponsored by NSABP Foundation, which has 44 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00382070 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00382070's enrollment target sits among peer trials
3,966 38th of 1224 higher than 1,187 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
RECRUITING · Phase 3
-
Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy
RECRUITING · Phase 3
-
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
RECRUITING · Phase 3
-
A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer
RECRUITING · Phase 3
-
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00227253 · 4,000 participants
Chromosome 18 Clinical Research Center
- NCT00811148 · 4,000 participants
Florida Center for Brain Tumor Research
- NCT00897117 · 4,000 participants
Collecting and Analyzing Tissue Samples From Patients Undergoing Surgery for Non-Small Cell Lung Cancer
- NCT01399385 · 4,000 participants · NA
New Heart Imaging Techniques to Evaluate Possible Heart Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia